Skip to main content
. 2012 Jun 18;4(8):761–775. doi: 10.1002/emmm.201200244

Figure 1. Genetic loss of systemic SK1 inhibits tumour growth and/or progression.

Figure 1

  • A,B. Prostate tumour scores (A) and survival (B) of TRAMP+/+ (n = 10) versus TRAMP+/+/SK1−/− (n = 7) mice were measured for 12 months. Data are represented as mean ± SD. Error bars represent standard deviations. p < 0.05 (*) was considered significant.
  • C,D. S1P was measured using LC/MS/MS in serum obtained from WT and SK1−/− mice (C), or in tissues obtained from MB49-allograft-derived tumours (D), and normalized to Pi levels. Data are represented as mean ± SD. Error bars represent standard deviations. p < 0.05 (*) was considered significant.
  • E. Volumes of tumours derived from MB49 allografts grown in WT and SK1−/− ko mice were measured for 28 days. Data are represented as mean ± SD. Error bars represent standard deviations. p < 0.05 (*) was considered significant.